tradingkey.logo
搜尋

Aclarion Inc

ACON
添加自選
3.090USD
+0.070+2.32%
收盤 07/02, 13:00美東報價延遲15分鐘
7.55M總市值
虧損本益比TTM

Aclarion Inc

3.090
+0.070+2.32%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.32%

5天

+8.42%

1月

-12.46%

6月

-37.95%

今年開始到現在

-32.83%

1年

-58.52%

關鍵數據
3.045今開
3.110最高
21.27K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.87%換手率
3.020昨收
3.020最低
48.12K成交額
虧損本益比靜
0.38市淨率
0.00%股息率 TTM
-43.37%ROA
12.03052週最高
1.14量比
-7.05M淨利潤
2.44M總股本
-5.6302每股盈餘TTM
1.20Beta
-45.43%ROE
2.34052週最低
2.98%振幅
17.74%毛利率
7.55M總市值
-3.34回報/風險
4.32%風險率

TradingKey Aclarion Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Aclarion Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名207/387位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為7.50。中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Aclarion Inc評分

相關信息

行業排名
207 / 387
全市場排名
391 / 4565
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Aclarion Inc亮點

亮點風險
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
業績增長期
公司處於發展階段,最新年度總收入75.73K美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入75.73K美元
估值低估
公司最新PE估值-0.55,處於3年歷史低位
機構加倉
最新機構持股58.05K股,環比增加22.32%

分析師目標

基於 1 分析師
買入
評級
7.500
目標均價
+148.34%
漲幅空間

Aclarion Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Aclarion Inc簡介

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
公司代碼ACON
公司Aclarion Inc
CEONess (Brent)
網址https://aclarion.com/

常見問題

Aclarion Inc(ACON)的當前股價是多少?

Aclarion Inc(ACON)的當前股價是 3.09。

Aclarion Inc 的股票代碼是什麼?

Aclarion Inc的股票代碼是ACON。

Aclarion Inc股票的52週最高點是多少?

Aclarion Inc股票的52週最高點是12.03。

Aclarion Inc股票的52週最低點是多少?

Aclarion Inc股票的52週最低點是2.34。

Aclarion Inc的市值是多少?

Aclarion Inc的市值是7.55M。

現在Aclarion Inc(ACON)的股票是買入、持有還是賣出?

根據分析師評級,Aclarion Inc(ACON)的總體評級為買入,目標價格為7.50。

Aclarion Inc(ACON)股票的每股收益(EPS TTM)是多少

Aclarion Inc(ACON)股票的每股收益(EPS TTM)是-13.61。